unknown
Stage
1
Investors
About
eTheRNA Immunotherapies is a clinical-stage biotechnology company developing mRNA-based immunotherapies for cancer. Its TriMix platform combines three mRNAs (caTLR4, CD40L and CD70) to activate dendritic cells and induce antigen-specific T-cell responses against tumors.
Explore eTheRNA Immunotherapies's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.